UCB Sa operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Lonza Group AG
of SWITZERLAND
(2020
sales of 4.51 billion Swiss Francs [US$4.87 billion]
of which 99%
was Pharma&Biotech),
Biomerieux SA
of FRANCE
(3.12 billion Euros [US$3.64 billion]
of which 85%
was Diagnostic Clinical Equipment), and
Grifols SA
which is
based in SPAIN
(5.34 billion Euros [US$6.24 billion]
of which 79%
was Bioscience).
Sales Analysis.
During the second
quarter of 2021, sales at UCB Sa totalled
2.78 billion Euro.
This is
an increase of 6.5%
from the 2.61 billion Euro in sales at the company during the second quarter of 2020.
UCB Sa reported sales of 5.35 billion Euro (US$6.25 billion)
for the
year ending
December of 2020.
This
represents
an
increase of 8.8%
versus 2019, when the company's sales were 4.91 billion Euro.
Sales at UCB Sa have increased during each of the previous five years
(and since 2015, sales have increased a total of 38%).
Sales of Briviact saw an increase
that was more than double the company's growth rate: sales were up
30.3% in 2020, from
221.00 million Euro to 288.00 million Euro.
Not all segments of UCB Sa experienced an increase in sales in 2020:
sales of Other Products fell 18.6% to 358.00 million Euro.
UCB Sa also experienced decreases in sales in
Neupro (down 2.5% to 311.00 million Euro)
.